DK2057184T3 - Cykliske antiotensinanaloge - Google Patents

Cykliske antiotensinanaloge

Info

Publication number
DK2057184T3
DK2057184T3 DK07808529.7T DK07808529T DK2057184T3 DK 2057184 T3 DK2057184 T3 DK 2057184T3 DK 07808529 T DK07808529 T DK 07808529T DK 2057184 T3 DK2057184 T3 DK 2057184T3
Authority
DK
Denmark
Prior art keywords
analogs
cyclic
antiotensin
analogues
agonistic
Prior art date
Application number
DK07808529.7T
Other languages
English (en)
Inventor
Marijke Haas
Leonardus Kluskens
Anneke Kuipers
Rick Rink
Sieger Nelemans
Gert Nikolaas Moll
Original Assignee
Applied Nanosystems Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Nanosystems Bv filed Critical Applied Nanosystems Bv
Application granted granted Critical
Publication of DK2057184T3 publication Critical patent/DK2057184T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK07808529.7T 2006-08-08 2007-08-07 Cykliske antiotensinanaloge DK2057184T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NL2006/000414 WO2008130217A1 (en) 2006-08-08 2006-08-08 Cyclic angiotensin analogs
PCT/NL2007/050396 WO2008018792A2 (en) 2006-08-08 2007-08-07 Cyclic angiotensin analogs

Publications (1)

Publication Number Publication Date
DK2057184T3 true DK2057184T3 (da) 2011-05-02

Family

ID=37809189

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07808529.7T DK2057184T3 (da) 2006-08-08 2007-08-07 Cykliske antiotensinanaloge

Country Status (10)

Country Link
US (1) US8835375B2 (da)
EP (1) EP2057184B1 (da)
CN (1) CN101573373B (da)
AT (1) ATE497969T1 (da)
AU (1) AU2007282221B2 (da)
CA (1) CA2660208C (da)
DE (1) DE602007012443D1 (da)
DK (1) DK2057184T3 (da)
NZ (1) NZ574876A (da)
WO (2) WO2008130217A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2393455T3 (es) * 2008-09-12 2012-12-21 Charité-Universitátsmedizin Berlin (Charité) Uso de un agonista del receptor Ang-(1-7) en lesiones pulmonares agudas
EP2376101B1 (en) * 2008-12-29 2015-12-02 Trevena, Inc. Beta-arrestin effectors and compositions and methods of use thereof
EP2267003A1 (en) 2009-06-24 2010-12-29 Applied NanoSystems B.V. Biologically produced cyclic affinity tags
EP2455388A1 (en) * 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
EP2578599A1 (en) * 2011-10-07 2013-04-10 LanthioPep B.V. Cyclic analogs of GLP-1 and GLP-1 related peptides
CN104168907A (zh) 2012-01-31 2014-11-26 特维娜有限公司 β-抑制蛋白效应器及其组合物与使用方法
EP2819687A4 (en) * 2012-02-10 2015-09-30 Tarix Pharmaceuticals Ltd COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL VASCULAR DISEASE
US20130230485A1 (en) 2012-03-01 2013-09-05 Kathleen E. Rodgers Methods for Treating Patients Undergoing Multi-Cycle Chemotherapy
WO2013154983A1 (en) 2012-04-09 2013-10-17 Rodgers Kathleen E Molecular markers of endothelial dysfunction in gestational diabetes
EP2849773A1 (en) 2012-05-14 2015-03-25 University of Southern California Methods for limiting development of a skin wound
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
WO2014021942A1 (en) 2012-08-01 2014-02-06 University Of Southern California Methods for limiting development of neurodegeneration
CA2884792A1 (en) * 2012-09-17 2014-03-20 Tarix Pharmaceuticals Ltd. Oral formulations of angiotensin
US8633158B1 (en) * 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
EP2967049B1 (en) 2013-03-15 2020-09-02 University Of Southern California Methods, compounds, and compositions for the treatment of angiotensin-related diseases
CA2902619A1 (en) 2013-03-15 2014-09-25 University Of Southern California Methods for treating multiple sclerosis
JP2016520592A (ja) * 2013-05-24 2016-07-14 タリックス ファーマシューティカルズ リミテッド マルファン症候群および関連障害の処置におけるアンジオテンシンペプチド
ES2771749T3 (es) * 2013-12-18 2020-07-07 The George Washington Univ A Congressionally Chartered Not For Profit Corporation Angiotensina II en combinación para el tratamiento de hipotensión
JP2017506235A (ja) 2014-02-07 2017-03-02 トレベナ・インコーポレイテッドＴｒｅｖｅｎａ， Ｉｎｃ． ベータ−アレスチンエフェクターの結晶性および非晶質形態
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
AU2015264367A1 (en) 2014-05-19 2016-12-15 Trevena, Inc. Synthesis of Beta-Arrestin Effectors
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
AU2015294371B2 (en) * 2014-07-21 2018-02-01 The Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides and methods for using and producing the same
JP2022542437A (ja) 2019-08-02 2022-10-03 ランティオペプ ベスローテン ヴェンノーツハップ 癌の処置に用いるアンジオテンシン２型（ａｔ２）受容体アゴニスト

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028168A (en) * 1991-08-09 2000-02-22 Winfried Kolbeck Lanthionine bridged peptides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
SE9700301D0 (sv) * 1997-01-31 1997-01-31 Astra Ab New compound
CA2339330A1 (en) * 1998-08-13 2000-02-24 University Of Southern California Methods to increase blood flow to ischemic tissue
US6861236B2 (en) * 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way

Also Published As

Publication number Publication date
AU2007282221A1 (en) 2008-02-14
WO2008130217A1 (en) 2008-10-30
WO2008018792A3 (en) 2008-04-03
CN101573373B (zh) 2014-04-30
CN101573373A (zh) 2009-11-04
DE602007012443D1 (de) 2011-03-24
EP2057184B1 (en) 2011-02-09
US8835375B2 (en) 2014-09-16
AU2007282221B2 (en) 2010-09-02
ATE497969T1 (de) 2011-02-15
NZ574876A (en) 2011-03-31
CA2660208A1 (en) 2008-02-14
US20100055146A1 (en) 2010-03-04
WO2008018792A2 (en) 2008-02-14
CA2660208C (en) 2012-05-22
EP2057184A2 (en) 2009-05-13

Similar Documents

Publication Publication Date Title
DK2057184T3 (da) Cykliske antiotensinanaloge
NZ707292A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
ZA201001054B (en) Peptide with reduced dimer formation
CL2007002327A1 (es) Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc.
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
WO2006097536A3 (en) Dimeric peptide agonists of the glp-1 receptor
PE20130615A1 (es) Polipeptidos del receptor de activina variante y uso de los mismos
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
EP1804823A4 (en) NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS
EP1751179A4 (en) PEPTIDES DERIVED FROM THE CASEIN AND THEIR THERAPEUTIC USES
IL192373A (en) Arginine cyclic peptides and their use in the treatment of fungal infections
ATE516853T1 (de) Zyklische peptid-cxcr4-antagonisten
MY152824A (en) Combination of hcv ns3 protease inhibitor with interferon and ribavirin.
WO2008052185A3 (en) Materials and methods for the treatment of celiac disease
CY1110980T1 (el) Εμβολιο συνδυασμων πεπτιδιων εναντια στην αλλεργια απο γατες
MY142044A (en) Endoparasiticidal compositions for topical application
NZ607892A (en) Tfpi inhibitors and methods of use
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
ATE457736T1 (de) Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
BR112012007563A2 (pt) peptídeos sintéticos antagonistas de miostatina
WO2008093058A3 (en) Peptides and their use
EA201000329A1 (ru) Циклические депсипептиды
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
EP2402364A3 (en) A nonapeptide with anti-tumour activity
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof